Overview

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This clinical study will be a prospective, placebo-controlled, double-blind, randomized and centrally evaluated intra-individual comparative study to assess the safety and efficacy of AR/101 concomitantly administered with Standard of Care (SoC) in accelerating re epithelialization of split thickness wounds compared with placebo and concomitantly with SoC, in the pannus of volunteers undergoing elective abdominoplasty.
Phase:
Phase 2
Details
Lead Sponsor:
Arava Bio Tech Ltd.
Collaborator:
Cato Research